idiopathic%20pulmonary%20fibrosis
IDIOPATHIC PULMONARY FIBROSIS

Idiopathic pulmonary fibrosis is the progressive parenchymal scarring & loss of pulmonary function due to unidentifiable cause of lung injury.

It is a specific form of chronic fibrosing interstitial pneumonia with the histopathologic characteristics of usual interstitial pneumonia.

Approximately 5% of patients are asymptomatic. Common signs and symptoms are exertional dyspnea, nonproductive cough, finger clubbing and bilateral inspiratory crackles.

Surgical Intervention

 Lung Transplantation

  • May be considered in idiopathic pulmonary fibrosis patients with moderate to severe disease
  •  Since idiopathic pulmonary fibrosis is a potentially rapid & progressive disease, the evaluation & opportunity for a transplantation is limited & is much shorter for patients with  idiopathic pulmonary fibrosis
    • Decision to undergo lung transplantation should be made within 3-6 months after initial diagnosis
    • Expected median survival is 34 months & applies after initial diagnosis of idiopathic pulmonary fibrosis
    • Once diagnosed, the patient must be referred immediately to a transplant center for evaluation
  •  A completion of at least 3 months of rehabilitation program is required before the patient may be considered for its eligibility for a transplantation
  • Patients who are 75 years old are still accepted in the transplant program
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
  • Patients with acute exacerbation of idiopathic pulmonary fibrosis do not benefit from lung transplantation as perioperative risks are greater
    • ICU patients or those who are hooked to a mechanical ventilator may be at risk if subjected to a transplantation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 28 Sep 2020
With much remains controversial regarding the possible transmission route of SARS-CoV-2 virus, a study reveals yet another surprise worthy of caution in the hospital setting.
Audrey Abella, 22 Sep 2020
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.